Clinical Trials / Research
Newark Beth Israel Medical Center has a long standing history of participating
in research for cancer and blood disorders. At present we conduct a wide
variety of clinical trials in cancer and blood disorders.
For more information about our clinical trials, please call
Open Protocols - Updated February 1, 2017
We are a member of NSABP and have open clinical trials.
NSABP B-51/RTOG 1304:
A Randomized Phase IIIClinical Trial Evaluating Post-Mastectomy Chestwall
and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients
with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert
to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
NSABP B-53/S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the
Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients
with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer
NSABP B-55/BIG 6-13
A Randomized, Double-Blind, Parallel Group, Placebo Controlled Multi-Centre
Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo
as Adjuvant Treatment in Patients with Germline
BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed
Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin
Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin
for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without
ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or
BRCA Mutation-Associated Breast Cancer
RTOG 0848: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant
Treatment, For Patients with Resected Head of Pancreas of Adenocarcinoma.
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib
Following Completion of Standard Chemotherapy for Patients with Stage
III Colon Cancer (ARGO)
E1A11:Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone
(VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed
by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients
with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
ECOG E3A06: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in
Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
S1403:A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib
Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive
Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124).
S1400:PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS
CELL LUNG CANCER (LUNG-MAP)
S1400I: “A Phase III Randomized Study of Nivolumab Plus Ipilimumab
Versus Nivolumab for Previously Treated Patients with Stage IV Squamous
Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)”
Initial Activation Effective 12/18/15.
Patient & Clinician Videos
For more information about clinical trials, watch these videos from the
American Cancer Society:
Exploring the Options: Clinical Trials: in this video, learn more about cancer clinical trails options from the
American Cancer Society.
Raising Awareness about Clinical Trials: A Video for Clinicians:in this video, learn more about how clinicians can help raise awareness
for cancer clinical trails options from the American Cancer Society.